Alexander Fosså

Oslo University Hospital — Norway

Medicine · Health Sciences

36h-index6.8kcitations194works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(115), Lung Cancer Treatments and Mutations(37), CNS Lymphoma Diagnosis and Treatment(33), Viral-associated cancers and disorders(30), Chronic Lymphocytic Leukemia Research(16)

Publications191 total

Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey.
PubMed·2026
A Phase II Study of 177Lu–Lilotomab Satetraxetan, a CD37 Antibody–Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients
Pharmaceuticals·2026Open Access
Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7
Blood·2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial
Blood·2025· 2 cited
2879P Changes in chronic fatigue and other late effects during a 5-year period, and the effect on functioning and work ability in long-term survivors of Hodgkin lymphoma
Annals of Oncology·2025
2806MO Effect of a multidisciplinary intervention on fatigue in lymphoma survivors with chronic fatigue- a randomized controlled trial (REFUEL)
Annals of Oncology·2025
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced‐stage Hodgkin lymphoma in older patients
HemaSphere·2025· 1 citedOpen Access
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
Open Access CRIS of the University of Bern·2025Open Access
Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial
Journal of Clinical Oncology·2025· 5 cited
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
The Lancet Oncology·2025· 4 citedOpen Access
Quantitative Deauville Scoring to Uncover Prognostic Information from <sup>18</sup>F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial
Journal of Nuclear Medicine·2025· 3 citedOpen Access
Effects of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Chronic Fatigue: Protocol for a Randomized Controlled Trial (REFUEL)
JMIR Research Protocols·2025Open Access
Response to Comment on: A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma
Haematologica·2025Open Access
868 | FERTILITY‐FOCUSED FINDINGS FROM THE INSIGHTFUL STUDY: CLINICIANS’ REFLECTIONS ON COUNSELLING, SUPPORT, AND FOLLOW‐UP CARE PROVIDED THROUGHOUT ONCOLOGIC INTERVENTION
Hematological Oncology·2025Open Access
356 | METABOLIC TUMOR VOLUME IN OLDER PATIENTS WITH ADVANCED‐STAGE CLASSIC HODGKIN LYMPHOMA: RESULTS FROM THE GHSG HD21 TRIAL
Hematological Oncology·2025Open Access
A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma
Haematologica·2025· 1 citedOpen Access
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial
HemaSphere·2025· 3 citedOpen Access
Digital health interventions to treat overweight and obesity in children and adolescents: An umbrella review
Obesity Reviews·2025· 6 citedOpen Access
Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry
Blood Advances·2025· 13 citedOpen Access
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma
JAMA Oncology·2025· 3 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Sophie D. Fosså(10), Harald Holte(10), Frits van Rhee(9), David C. Fajgenbaum(8), Sheila K. Pierson(6), Amy Chadburn(6), Øystein Fluge(6), Gordan Srkalović(5), Raymond Wong(5), Jason R. Ruth(5), Corey Casper(5), Éric Oksenhendler(5), Megan S. Lim(5), Arne Kolstad(5), Cecilie E. Kiserud(5), Thomas S. Uldrick(4), Mary Jo Lechowicz(4), Sunita D. Nasta(4), Raj Jayanthan(4), Angela Dispenzieri(4)